Compare NWGL & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NWGL | AIMD |
|---|---|---|
| Founded | 2008 | 1984 |
| Country | Macau | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.1M | 10.6M |
| IPO Year | 2022 | 2008 |
| Metric | NWGL | AIMD |
|---|---|---|
| Price | $1.61 | $1.35 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.6M | 19.7K |
| Earning Date | 05-21-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $124,157.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 498.95 |
| 52 Week Low | $0.19 | $1.26 |
| 52 Week High | $1.82 | $4.44 |
| Indicator | NWGL | AIMD |
|---|---|---|
| Relative Strength Index (RSI) | 74.59 | 40.98 |
| Support Level | $1.11 | $1.31 |
| Resistance Level | N/A | $1.66 |
| Average True Range (ATR) | 0.27 | 0.08 |
| MACD | 0.05 | -0.00 |
| Stochastic Oscillator | 79.67 | 6.25 |
CL Workshop Group Ltd, formerly Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers.
Ainos Inc is a dual-platform company advancing artificial intelligence based smelltech technologies and immune therapeutics. Its primary strategic focus is the commercialization of its proprietary scent digitization platform, AI Nose, while the company also continue to develop therapeutic assets based on its low-dose oral interferon program, VELDONA. Its core technology platform, AI Nose, is an AI-based electronic olfaction system that integrates gas sensor arrays with proprietary artificial intelligence models, which it refers to as a smell language model (SLM), to digitize scent and volatile organic compound (VOC) signals into Smell ID, a machine-readable data format.